Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Letter

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 04, 2023 9:15am

204 Views

Post# 35202328

RE:RE:RE:Letter

I just read the letter a second time and I still think the Nash Rabbit is the next positive surprise!!

R&D activities will be reduced and cash generation will be used to expand the product line .... thereby leveraging the sales organization

palinc2000 wrote:
13%_19% Revenue growth guidance
-looking for other products to commercialize
Post pandemic allows Paul to build a cash generating company ...... It would be nice if they were to over deliver on the guidance
Finally focusing on things over which they have control

-Nash still alive but very conservative comments

Strict contril of expenses on Th1902

Cash generation and cash conservation are the main take aways ....